Keyword: Aurobindo Pharma
Merck gets half of Lenvima's sales in $5.8 billion deal; Juno and WuXi's CAR-T JV got $90 million; FDA approved Taiwanese firm's HIV drug.
Regulatory problems are piling up for the sterile manufacturing operations of India’s Aurobindo, which has had another plant cited by the FDA.
Sanofi, aiming to sharpen its focus by offloading its EU generics, is reportedly drawing shoppers from across the globe. The deal could be worth $2B.
Japan’s JSR bought Crown Biosciences, Aurobindo and Dr. Reddy’s responded to Orchid Pharma report, Tessa raised $80 million.
Aurobindo and Dr. Reddy’s each responded to a report by the Economic Times that said both were front-runners to buy bankrupt Orchid Pharma.
Price-fixing allegations against generics makers just keep piling up, with Mylan, Teva and other players targeted in yet another lawsuit.
Eli Lilly’s storied erectile dysfunction med Cialis will keep exclusive protections a little while longer.
Eli Lilly’s $500 million-plus ADHD med Strattera succumbed to generics Tuesday as four drugmakers won FDA green lights for their copycat.
Wockhardt reported a widened Q4 loss, Takeda penned a T-cell platform deal, and the FDA approved Mitsubishi’s ALS drug Radicava.
The FDA has cited an Aurobindo sterile manufacturing plant in India for not doing everything it can to prevent contamination, according to a new report.